Artivion | CRY - Cash And Equivalent


Artivion reported $48.4M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Abbott USD 4.05B 1.05B Sep/2026
Accuray USD 41.29M 22.05M Dec/2025
AngioDynamics USD 41.64M 14.26M Sep/2025
Artivion USD 48.4M 28.92M Sep/2026
AtriCure USD 187.03M 19.24M Sep/2026
Baxter International USD 1.98B 175M Sep/2026
Becton, Dickinson and Co. USD 725M 17M Sep/2026
Boston Scientific USD 609M 70M Sep/2026
Edwards Lifesciences USD 3.11B 210.8M Sep/2026
Inogen USD 106.48M 2.79M Sep/2025
Integra LifeSciences USD 252.26M 37.85M Sep/2026
J&J USD 16.91B 3.51B Sep/2026
Mesa Laboratories USD 28.98M 8.55M Dec/2025
Orthofix International USD 86.32M 17.49M Sep/2026
Pfizer USD 1.82B 848M Sep/2026
ResMed USD 1.01B 458.49M Sep/2026
Stryker USD 3.27B 120M Sep/2026
Tandem Diabetes Care USD 72.84M 10.02M Sep/2026
Teleflex USD 430.46M 130.31M Sep/2026
Terumo JPY 314.63B 34.14B Jun/2026
Trinity Biotech USD 5.14M 3.8M Dec/2025